CCND1 as a Radioligand Therapy Target
CCND1, cyclin D1, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, CCND1 staining is highest in kidney cancer (100% of samples positive), gastric cancer (100% of samples positive) and lymphoma (83% of samples positive). Clinical status: Clinical-stage (up to phase 1, any modality).
Is CCND1 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in kidney cancer, 100% of samples positive.
- ❔ Internalization: Not yet assessed.
- ✅ Clinical precedent: Clinical-stage (up to phase 1, any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
CCND1 expression in cancer
Protein expression of CCND1 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Kidney Cancer | 0.97 | High | 100% |
| Gastric Cancer | 0.88 | High | 100% |
| Lymphoma | 0.83 | High | 83% |
| Colorectal Cancer | 0.75 | High | 100% |
| Thyroid Cancer | 0.75 | High | 100% |
| Cervical Cancer | 0.70 | High | 100% |
| Bladder Cancer | 0.70 | High | 91% |
| Glioma | 0.69 | High | 100% |
| Head and Neck Cancer | 0.67 | High | 100% |
| Ovarian Cancer | 0.67 | High | 100% |
| Liver Cancer | 0.67 | High | 92% |
| Lung Cancer | 0.61 | High | 92% |
| Pancreatic Cancer | 0.58 | High | 83% |
| Melanoma | 0.56 | High | 83% |
| Testicular Cancer | 0.56 | High | 83% |
| Endometrial Cancer | 0.56 | High | 83% |
| Prostate Cancer | 0.47 | Medium | 83% |
| Breast Cancer | 0.42 | Medium | 83% |
| Skin Cancer | 0.39 | Medium | 58% |
| Neuroendocrine Tumors | 0.33 | Medium | 50% |
Is CCND1 internalized?
Nuclens has not yet extracted internalization evidence for CCND1. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a full analysis to pull the latest literature.
CCND1 clinical trials
Clinical-stage (up to phase 1, any modality). Nuclens hasn't indexed trials for CCND1 yet. Search ClinicalTrials.gov for CCND1 trials.
CCND1 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See CCND1 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
CCND1 gene essentiality (DepMap)
CRISPR knockout effect across 1258 cancer cell lines: -1.25 (essential, below −0.5). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related kidney cancer radioligand targets
EGFR · c-MET (MET) · HER3 (ERBB3) · STEAP2 · ITGAV · Mesothelin (MSLN) · SSTR2 · HER2 (ERBB2)
See all radioligand therapy targets in kidney cancer.
See how CCND1 ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.